Ligand based dendritic systems for tumor targeting
Abhinav Agarwal1, Surbhi Saraf, Abhay Asthana
1Department of Pharmaceutical Sciences, Dr. H. S. Gour University, Sagar 470003, MP, India.
Abstract:
Medications that can selectively target tumors at the same time avoid access of the drug to nontarget areas, employ utilization of homing devices termed as ligands, that can bind to specific epitopes expressed on the surface of the necrotic mass of cells. Molecular signatures for transferrin, Epidermal Growth Factor, Sialic Lewis and folic acid are expressed on the surface of these cells. Dendrimers are nanosized, non-immunogenic, and hyper-branched vehicles that can be efficiently tailored for spatial distribution of bioactives, thereby reducing untoward cytotoxicity on normal cells. These nanoparticulate drug delivery vehicles provide a unique platform that has precisely placed functional groups so that multiple copies of ligands can be attached to it and facilitate targeting to the tumor surface or neo-vascularizing vessels proliferating around these cells. The article reviews the scope of ligand based dendritic system as a prospective for delivery of anti-cancer drugs, via active targeting with interception of minimal side effects.
Insights
Dendrimers, a type of nanoparticle, can be engineered with ligands to target cancer cells specifically. This targeted drug delivery system minimizes side effects on healthy tissues, offering a promising approach for anti-cancer therapies.
Area of Science:
- Nanotechnology
- Oncology
- Drug Delivery
Background:
- Tumor cells express specific molecular signatures like transferrin and folic acid.
- Conventional chemotherapy causes significant side effects due to non-specific drug distribution.
Purpose of the Study:
- To review the potential of ligand-based dendritic systems for targeted anti-cancer drug delivery.
- To highlight the advantages of dendrimers in reducing off-target toxicity.
Main Methods:
- Utilizing dendrimers as nanosized, non-immunogenic drug carriers.
- Functionalizing dendrimers with specific ligands (e.g., transferrin, folic acid) for active targeting.
- Attaching anti-cancer drugs to the dendrimer platform for controlled release.
Main Results:
- Dendrimers can be tailored to attach multiple ligands for enhanced tumor cell binding.
- Targeted delivery via ligands reduces drug exposure to healthy tissues.
- This approach offers a strategy for precise spatial distribution of bioactives.
Conclusions:
- Ligand-functionalized dendrimers represent a promising platform for active targeting of anti-cancer drugs.
- This targeted approach has the potential to significantly minimize adverse side effects.
- Dendritic systems offer a versatile vehicle for developing next-generation cancer therapeutics.
Related Concept Videos
Modified-Release Drug Delivery Systems: Site-Targeted
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Site-Targeted Drug Delivery Systems: Polymeric Carriers


